0932 ET - Eli Lilly is slightly higher is early trading after another blowout quarter driven by GLP-1 drugs. 4Q revenue rises 45% to $13.53 billion. Revenue from new products climbs by $3.15 billion to $5.64 billion, driven Zepbound and Mounjaro. Lilly's fortunes echo those of Danish rival Novo Nordisk, which sold$4.71 billion of its Ozempic drug in 4Q. Lilly shares have more than quintupled in the last five years. Rival drug makers, such as Novartis, have admitted hunting for obesity drugs of their own. Lilly and Novo have major first-mover advantage, with smaller players such as Viking Therapeutics still playing catchup. Anya Schiess, a partner at JPMorgan's asset management unit, is among those who have predicted GLP-1s will be the best-selling class of drugs yet. (rob.curran@dowjones.com)
(END) Dow Jones Newswires
February 06, 2025 09:32 ET (14:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.